Charité — Universitätsmedizin Berlin Joins Thermo Fisher Scientific’s Next-Generation Sequencing Center of Excellence Program

Charité — Universitätsmedizin Berlin Joins Thermo Fisher Scientific’s Next-Generation Sequencing Center of Excellence Program Leading oncology research hospital becomes new member to advance Oncomine™ liquid biopsy and immuno-oncology diagnostics BERLIN and CARLSBAD, Calif., March 15, 2018 /PRNewswire/ — Thermo Fisher Scientific has named Charité – Universitätsmedizin Berlin as the newest member of its Next Generation Sequencing... Read more

Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract

MINNEAPOLIS, March 14, 2018 /PRNewswire/ — Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface. 3-D cell culture and organoid models of the gastrointestinal epithelium are quickly being adopted for toxicology, drug discovery, and disease modeling. These more complex models provide a tremendous benefit over cell line- and primary... Read more

Bruker and Evosep Announce New Integrated Clinical Research Proteomics Solution to Quantify Over a Thousand Proteins in Five Minutes

MINNEAPOLIS, March 12, 2018 /PRNewswire/ — At the 2018 US HUPO Conference, Bruker (NASDAQ: BRKR) and Evosep announce that they have executed a co-development and co-marketing agreement for the Evosep One chromatography system to work seamlessly with Bruker’s timsTOF Pro ultra-high resolution quadrupole time of flight mass spectrometer.  The timsTOF Pro is powered by TIMS... Read more

QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN’s GeneReader NGS System

MAR 12 2018 Hilden, Germany, and San Carlos, CA, March 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor... Read more

QIAGEN launches CE-IVD assay to detect Trichomonas vaginalis in both female and male patients on the QIAsymphony RGQ platform

MAR 05 2018 New artus® assay enables detection of T. vaginalis from a broad range of sample types and expands sexually transmitted infection (STI) menu Germantown, Maryland, and Hilden, Germany, March 5th, 2018 – QIAGEN today announced the European launch of the artus T. vaginalis QS-RGQ Kit, a CE-marked molecular diagnostic test for the qualitative detection of the... Read more

Millions of U.S. Allergy Sufferers Now Have Access to Advanced Diagnostic Tests

Millions of U.S. Allergy Sufferers Now Have Access to Advanced Diagnostic Tests PlushCare’s highly trained telehealth physicians can now conveniently order Thermo Fisher Scientific blood allergy tests for patient diagnosis and treatment WALTHAM, Mass., Feb. 21, 2018 /PRNewswire/ — Millions of undiagnosed allergy sufferers, including those affected by allergy induced asthma, can now access Thermo Fisher’s advanced... Read more

Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business

Cambridge, United Kingdom – 25 January 2018 –Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors. Dr Atkins has over 25 years’ experience as a global... Read more

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing... Read more